Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimidex in Girls with McCune-Albright Syndrome
NCT00055302Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2002
- Primary completion
- Feb 2006
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in McCune-Albright syndrome (MAS), sponsored by AstraZeneca. Primary endpoints: Change from baseline in vaginal bleeding at 12 months, Change from baseline in bone age at 12 months and 1 more. Started Aug 2002; status: completed.
02
Drugs
anastrozole
03
Conditions
McCune-Albright syndrome (MAS)
Beyond the preview
Go deeper on NCT00055302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055302.